An accurate, non-invasive approach to diagnose Cushing’s syndrome in at-risk populations
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
BACKGROUND The prevalence of Cushing's syndrome (CS) in at-risk populations in developing countries remains uncertain. Evening urinary cortisol (UFC(22-23)) and salivary cortisol after treatment with 1-mg DST (SAFdex) have seldom been used as diagnostic tools in these populations. OBJECTIVES (1) To establish the prevalence of CS in adults with cortisol-related morbidities using UFC22-23 and SAFdex as markers along with all first-line diagnostic tests recommended for CS; and (2) to assess the performance of each test and define a non-invasive diagnostic approach for CS in at-risk outpatient subjects. METHODS A total of 128 outpatients were evaluated, including type 1 and 2 diabetic patients with poor metabolic control (DM1 and DM2), hypertensive subjects with central obesity (HBP) and premenopausal women with osteoporosis (OS). Controls included 100 healthy volunteers and 23 patients with CS. Total urinary cortisol (UFC), UFC(22-23), late-night salivary cortisol (SAF23) and suppression of cortisol levels in saliva (SAFdex) and serum (Fdex) after treatment with 1-mg DST were assessed. RESULTS CS was diagnosed in one DM2 and one HBP patient; both women exhibited central obesity. Among CS patients, UFC showed more within-person variability than UFC(22-23) or SAF23. UFC(22-23) and SAF23 were positively and significantly correlated in all groups (r > or = 0.70; p < or = 0.0001). UFC(22-23) > 44.0 ng/mg creatinine or SAF23 > 3.8 nM were 100% sensitive (S) and specific (E) for CS. Furthermore, SAFdex > 2.0 nM or Fdex > 50.0 nM were 100% S and 97.3% E for CS. CONCLUSION CS was diagnosed in 1.5% of at-risk patients. The combination of UFC(22-23) or SAF23 with SAFdex offers a non-invasive diagnostic tool to assess cortisol nadir and feed-back status in outpatients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.
Nieman, L. K., Biller, B. M. K., Findling, J. W., Newell-Price, J., Savage, M. O., Stewart, P. M., & Montori, V. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0125 · Cited by 2,718 · cited 2×
“0 nM) obtained in this study are in agreement with data based on compilation studies [10].”
11β-Hydroxysteroid dehydrogenase type 1: a tissue specific regulator of glucocorticoid response
Tomlinson, J. W., Walker, E. A., Bujalska, I. J., Draper, N., Lavery, G. G., Cooper, M. S., Hewison, M., & Stewart, P. M. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0031 · Cited by 969 · cited 1×
“This worrisome clinical scenario might be ascribed to glucocorticoid sensitivity, which may differ among individuals, between tissues of the same individual or as a consequence of polymorphisms in the genes encoding the glucocorticoid receptor and 11-beta-hydroxysteroid-dehydrogenase type 1 [25,26].”
OMURA, M., SAITO, J., YAMAGUCHI, K., KAKUTA, Y., & NISHIKAWA, T. (2004) · Hypertension Research · doi:10.1291/hypres.27.193 · Cited by 562 · cited 1×
“In our study, CS was detected among patients lacking specific signs of hypercortisolism but with morbidities such as uncontrolled diabetes mellitus type 2 and resistant arterial hypertension of unknown aetiology associated with central obesity, in agreement with previous findings [1,3,6,7,9,24].”
Characterization of the normal temporal pattern of plasma corticosteroid levels.
KRIEGER, D. T., ALLEN, W., RIZZO, F., & KRIEGER, H. P. (1971) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-32-2-266 · Cited by 549
Occult Cushing’s syndrome in type-2 diabetes
Catargi, B., Rigalleau, V., Poussin, A., Ronci-Chaix, N., Bex, V., Vergnot, V., Gin, H., Roger, P., & Tabarin, A. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030254 · Cited by 287 · cited 2×
“Early diagnosis and effective treatment in the two newly diagnosed patients resulted in improvement of glycaemic control, arterial blood pressure and obesity, as previously reported [1,2,9].”
Diagnosis and Treatment of Subclinical Hypercortisolism
Chiodini, I. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2722 · Cited by 279
Clinical Features Associated with Glucocorticoid Receptor Polymorphisms: An Overview
Manenschijn, L., van den Akker, E. L. T., Lamberts, S. W. J., & van Rossum, E. F. C. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05013.x · Cited by 249
Leibowitz, G., Tsur, A., Chayen, S. D., Salameh, M., Raz, I., Cerasi, E., & Gross, D. J. (1996) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1996.737558.x · Cited by 180 · cited 2×
“In our study, CS was detected among patients lacking specific signs of hypercortisolism but with morbidities such as uncontrolled diabetes mellitus type 2 and resistant arterial hypertension of unknown aetiology associated with central obesity, in agreement with previous findings [1,3,6,7,9,24].”
Elevated late-night salivary cortisol levels in elderly male type 2 diabetic veterans.
Liu, H., Bravata, D. M., Cabaccan, J., Raff, H., & Ryzen, E. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02395.x · Cited by 178
Viardot, A., Huber, P., Puder, J. J., Zulewski, H., Keller, U., & Müller, B. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2264 · Cited by 172 · cited 1×
“80, as we previously reported [9,17], in agreement with others [28,29].”
Cited by
Prevalence of endocrine disorders in obese patients: systematic review and meta-analysis
van Hulsteijn, L. T., Pasquali, R., Casanueva, F., Haluzik, M., Ledoux, S., Monteiro, M. P., Salvador, J., Santini, F., Toplak, H., & Dekkers, O. M. (2020) · European Journal of Endocrinology · doi:10.1530/eje-19-0666 · Cited by 103
Accuracy of laboratory tests for the diagnosis of Cushing syndrome
Galm, B. P., Qiao, N., Klibanski, A., Biller, B. M. K., & Tritos, N. A. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa105 · Cited by 100
Biochemical diagnosis of Cushing’s disease: Screening and confirmatory testing
Petersenn, S. (2021) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2021.101519 · Cited by 33
Hinojosa-Amaya, J. M., González-Colmenero, F. D., Alvarez-Villalobos, N. A., Salcido-Montenegro, A., Quintanilla-Sánchez, C., Moreno-Peña, P. J., Manzanares-Gallegos, D. M., Gutiérrez-Dávila, L. F., Castillo-Morales, P. L., García-Campa, M., et al. (2024) · Pituitary · doi:10.1007/s11102-024-01408-w · Cited by 14
Metadata
- Authors
- Cardoso, E. M. L., Arregger, A. L., Monardes, G., & Contreras, L. N.
- Venue
- Steroids
- Publisher
- Elsevier BV
- Published
- 2013-05
- Volume
- 78
- Issue
- 5
- Pages
- 476-482
- ISSN
- 0039-128X (ISSN-L)
- OpenAlex
- W2049330599
- Cited by
- 8
- References
- 16
- FWCI
- 0.47
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.